Biologic Effects of Anti–Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma

By Régis Bataille, Bart Barlogie, Zhao Yang Lu, Jean-François Rossi, Thierry Lavabre-Bertrand, Thad Beck, John Wijdenes, Jean Brochier, and Bernard Klein

In patients with advanced multiple myeloma (MM) there is an excess of production of interleukin-6 (IL-6) in vivo, and elevated serum levels are associated with plasmablastic proliferative activity and short survival. These data prompted us to perform a clinical trial with a murine anti–IL-6 monoclonal antibody (MoAb) to neutralize the excess of this putatively deleterious factor in these patients. Ten MM patients with extramedullary involvement frequently were treated with anti–IL-6 MoAb. The MoAb was administered intravenously to 9 patients: 1 patient with malignant pleural effusion received intrapleural therapy. Of the 3 patients who succumbed to progressive MM after less than 1 week of treatment (including the only 1 treated locally), 2 with evaluable data exhibited marked inhibition of plasmablastic proliferation. Among the 7 patients remaining more homogeneous receiving the anti–IL-6 MoAb for more than 1 week, 3 had objective antiproliferative effect marked by a significant reduction of the myeloma cell labelling index within the bone marrow. One of these 3 patients achieved a 30% regression of tumor mass. However, none of the patients studied achieved remission or improved outcome as judged by standard clinical criteria. Of major interest, objective antiproliferative effects were associated with complete inhibition of C-reactive protein (CRP) synthesis and low daily IL-6 production in vivo. On the other hand, the lack of effect in 4 patients was associated with a higher IL-6 production and inability of the MoAb to neutralize it. Anti–IL-6 was also associated with resolution of low-grade fever in all the patients and with worsening thrombocytopenia and mild neutropenia. The generation of human antibodies to Fc fragment of the murine anti–IL-6 MoAb observed in 1 patient was associated with dramatic progression. These data show that anti–IL-6 MoAb can suppress the proliferation of myeloma cells and underscore the biologic role of IL-6 for myeloma growth in vivo. Furthermore, suppression of CRP and worsening of neutropenia/thrombocytopenia both indicate that IL-6 is critically involved in acute-phase responses and granulopoiesis/thrombopoiesis.

© 1995 by The American Society of Hematology.

Interleukin-6 (IL-6), a pleiotropic cytokine produced by a range of cells, plays a central role in both host defense mechanisms and acute-phase responses.1 Pioneering studies have shown that this cytokine controlled the proliferation2,5 but did not induce the differentiation6 of immature myeloma cells in vitro. First, anti–IL-6 MoAb blocked the spontaneous proliferation of freshly explanted myeloma cell in short-term cultures and addition of exogeneous IL-6 further increased it.7,8 Second, myeloma cell lines whose proliferation is dependent on addition of exogeneous IL-6 have been obtained from every patient with extramedullary proliferation.9 All studies agreed that large amounts of IL-6 are produced by the tumoral microenvironment in response to stimulating myeloma cells.3,9,10 Several studies have reported an autocrine production of IL-6 by the myeloma cells themselves.7,11 However, this production was only very minor (1/1,000) as compared with that of the tumoral microenvironment. For these reasons, these studies could not exclude a minor contamination by environmental cells or more simply a weak activation of IL-6 gene in myeloma cells by exogeneous IL-6, as has been previously reported.12 The involvement of this cytokine in vivo is supported by the relationship of increased IL-6 serum levels to in vivo tumor cell kinetics, disease severity, and survival of patients with multiple myeloma (MM).13,14 These data led us to develop a clinical trial to define the effects of a murine anti–IL-6 monoclonal antibody (MoAb) in patients with advanced MM (mainly plasma cell leukemia). The rationale of this project was also supported by data obtained in mice showing that (1) IL-6 is a major paracrine plasmacytoma growth factor and that (2) anti–IL-6 and anti–IL-6 receptor MoAbs significantly inhibit the in vivo expansion of plasmacytomomas and improve the survival of inoculated mice.15

Patients, Materials, and Methods

Patients

Nine patients with advanced and progressive MM, mainly primary and secondary plasma cell leukemia (PCL) (n = 6), refractory to standard chemotherapy and with a life expectancy less than 1 month were treated with anti–IL-6 MoAb. The clinical course of a tenth patient treated similarly and previously reported has been included in the current study, considering new data on IL-6 production in vivo.16 Written informed consent was obtained from all the patients. Selected pretreatment characteristics of the 10 patients are summarized in Tables 1 and 2. All but 1 patient were treated with intravenous (IV) B-E8 anti–IL-6 MoAb, usually at a standard dose of 20 mg/day for at least 4 days (up to 68 days). One patient (no. 3) received B-E8 intrapleurally for a malignant pleural effusion at a daily dose of 20 mg for 3 days. Response to treatment was evaluated using standard criteria, including performance status, body temperature, weight, and improvement of symptoms such as anemia, hypercalcemia, occurrence of infections, and regression of monoclonal component and myeloma cell mass.

Materials and Methods

Infection of anti–IL-6 MoAb. Injection of anti–IL-6 MoAb was performed in vivo as previously described.16 Nine of the 10 patients

From the Laboratoire Central d’Hématologie et Laboratoire d’Oncogénèse Immunohématologique-Institut de Biologie, Nantes, France; Arkansas Cancer Research Center, Little Rock, AR; INSERM U.291, Immunopathologie des Maladies Tumorales et Auto-immunes, Montpellier, France; and Innothérapie, Besançon, France. Submitted June 16, 1994; accepted February 27, 1995.

Supported by grants from l’Association Pour la Recherche sur le Cancer, la Ligue Nationale de Lutte contre le Cancer (Paris, France), and la Ligue Régionale de Lutte contre le Cancer (Nantes, France).

Address reprint requests to Régis Bataille, MD, PhD, Laboratoire central d’Hématologie, Institut de Biologie, 9 quai Moncousu, 44035 Nantes Cédex 01, France.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1995 by The American Society of Hematology.

0006-4971/95/8602-0011$3.00/0

Blood, Vol 86, No 2 (July 15), 1995; pp 685-691
An anti-IL-6 MoAb was selected to provide serum concentrations similar to those known to inhibit myeloma cell proliferation in vitro and were adjusted according to patients' clinical status.

Anti-IL-6 MoAb. Anti-IL-6 MoAb (B-E8 and mab-8, both IgGk) were prepared by J. Wijdenes (Innotherapie, Besançon, France) and L. Aarden (Central Laboratory Blood Transfusion Service, Amsterdam, The Netherlands), respectively, by immunizing mice with rIL-6. These MoAb were purified and submitted to plating analyses required before use, as previously described. The purified MoAb were sterile and free of pyrogenic activity.

Collection of peripheral blood cells and serum samples. Peripheral blood or bone marrow samples for all studies, including pharmacokinetic studies, were collected at 7 AM, 1 hour before mab-8 or B-E8 injections. Peripheral blood and plasma were stored at −20°C until use. Peripheral blood, pleural effusion, or bone marrow mononuclear cells were obtained by centrifugation of heparinized samples over Ficoll-Hypaque gradients.

Proliferation and culture assays of myeloma cells. The percentages of myeloma cells were determined by cytoplasmic immunofluorescence using anti-k or anti-light chain antibodies directly coupled to fluorescein (Kallestadt, Austin, TX). The percentages of plasma cells in S phase (ie, the labeling index) were determined using an antibrucodexyuridine MoAb (Immunotech, Marseilles, France) and a rhodamine-labeled goat antimouse Ig (Jackson Laboratories, West Grove, PA) in a double fluorescence technique described elsewhere. Cells were cultured at 10^6 cells/mL in RPMI 1640 medium supplemented with 5 × 10−5 mol/L 2ME and 5% fetal calf serum for 5 days, hence referred to as culture medium. In some groups, 10 μg/mL of anti-IL-6 MoAb (mab-8 or B-E8) or of control purified murine serum IgG (Sigma Chemicals, St Louis, MO) was added at initiation of the cultures. To reverse the effect of anti-IL-6 MoAb, the MoAb was incubated with human rIL-6 (100 ng/mL) for 2 hours before being added to cultures. On day 5, the percentages of myeloma cells and myeloma cells in S phase were determined as described above.

Evaluation of circulating anti-IL-6 MoAb levels. Levels of circulating anti-IL-6 MoAb were determined by enzyme-linked immunosorbent assay (ELISA). Polystyrene plates (Immunon; Nunc, Kamstrup, Denmark) were coated overnight with purified goat IgG against mouse Ig (10 μg/mL in phosphate-buffered saline [PBS]; Tago Inc, Burlingame, CA) at room temperature. Plates were saturated with 1% bovine milk proteins (BMP) in PBS for 1 hour. After five washes in PBS containing 0.05% Tween 20 (Sigma Chemicals), 100 μL of the patient plasma diluted in PBS-BMP-Tween (1% BMP in PBS containing 0.05% Tween 20) was added for 1 hour at room temperature. Plates were washed five times with PBS-BMP-Tween before a solution containing peroxidase-conjugated goat antihuman Ig anti-IL-6 MoAb (Jackson Laboratories) was added for 1 hour and then washed again five more times. Reactivity was determined by the intensity of the enzymatic reaction to substrate O-phenylene diamine (for 20 minutes) measured by absorbance at 492 nm (Titertek Multiskan; Flow, Irvine, UK) after the addition of 50 μL 2 N H2SO4. Mouse Ig concentrations were calculated using a reference curve obtained with serial dilution of mab-8 or B-E8 MoAb.

Detection of human antibodies to anti-IL-6 MoAb. The presence of human antibodies to anti-IL-6 MoAb was also checked by ELISA. Plates (Immunon; Nunc) were coated with either 10 μg/mL (in PBS overnight at room temperature) of mab-8, B-E8, or a control MoAb of the same isotype (CD37, BL14) as IgG1. To ensure that the plates were coated with the same amount of each MoAb a peroxidase-conjugated goat antihuman MoAb (Jackson Laboratories) was used. Plates were saturated with PBS-BMP, and patient's serum samples (diluted 1/50 in PBS-BMP) were added for 1 hour at room temperature.
ANTI-IL-6 THERAPY IN MYELOMA

Table 2. Results of Anti-IL-6 Therapy in 7 Patients Receiving More Than 1 Week of Treatment

<table>
<thead>
<tr>
<th>Patients treated more than 1 week</th>
<th>Responsive to Anti-IL-6 MoAb</th>
<th>Unresponsive to Anti-IL-6 MoAb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ig type, light chain subtype</td>
<td>AK 5 6 AK 5 6 AK 5 6 AK 5 6</td>
<td>AK 5 6 AK 5 6 AK 5 6 AK 5 6</td>
</tr>
<tr>
<td>Types of tumors</td>
<td>MM MM Primary PCL Sec. PCL</td>
<td>Sec. PCL Sec. PCL Sec. PCL</td>
</tr>
<tr>
<td>Presenting fever (correction with MoAb)</td>
<td>- - + (yes) - - + (yes) + (yes)</td>
<td></td>
</tr>
<tr>
<td>Severe subsequent infection</td>
<td>- + - - + (death) - -</td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia (correction with MoAb)</td>
<td>- + (no) + (partial control) + (no) + (no) + (no) + (no)</td>
<td></td>
</tr>
<tr>
<td>Platelet counts (10^9/L) (% maximum suppression)</td>
<td>148 (45%) 272 (86%) 184 (56%) 88 (52%) 57 (37%) 17 (40%) 122 (35%)</td>
<td></td>
</tr>
<tr>
<td>Neutrophil counts (µL) (% maximum suppression)</td>
<td>1,845 (80%) 2,800 (78%) 3,000 (65%) 4,300 (95%) 3,784 (stable) 2,500 (70%) 2,700 (stable)</td>
<td></td>
</tr>
<tr>
<td>CRP serum level (pg/mL) (% maximum suppression)</td>
<td>5 (100%) 21 (100%) 90 (100%) 46 (96%) 90 (75%) 60 (88%) 123 (60%)</td>
<td></td>
</tr>
<tr>
<td>Daily in vivo IL-6 production (µg) Not done</td>
<td>1.7 4 &gt;46 &gt;165 &gt;47 &gt;341</td>
<td></td>
</tr>
<tr>
<td>Overall changes of myeloma Ig</td>
<td>/ -30% / / / /</td>
<td></td>
</tr>
<tr>
<td>Documented antiproliferative effects on myeloma cells</td>
<td>Yes Yes Yes No No No No</td>
<td></td>
</tr>
<tr>
<td>Survival (d)</td>
<td>93 45 128 17 11 17 13</td>
<td></td>
</tr>
</tbody>
</table>

*Due to toxic chemotherapy.
† Pretreatment values—CRP has been monitored as shown in the Fig 2. Platelet and neutrophil counts were monitored every day until death (patients no. 7, 8, 9, and 10), then every other day, then twice a week.

RESULTS

Anti-IL-6 MoAb Serum Concentrations and Immunization

In all patients receiving systemic therapy, serum anti-IL-6 MoAb (approximately 1 µg/mL) was detectable 24 hours after the first IV injection and increased progressively to an average value of 5 µg/mL on days 2 to 4 and to 5 to 17 µg/mL on days 7 and 8. No B-E8 MoAb was detected in the serum of the patient receiving intrapleural injections during the first 2 days. Concentrations of 6 to 17 µg/mL were sustained in 5 patients (no. 4, 5, 7, 8, and 10) and declined to undetectable levels in 1 patient (no. 9). Human antibodies to murine B-E8 MoAb were observed in 2 patients (no. 8 and 9) on days 9 to 11 resulting in rapid clearance of circulating anti-IL-6 MoAb despite continued drug administration in one patient (Fig 1). No anti-B-E8 or anti-mab-8 activity was found in the other patients' serum. For patient no. 6, the data have been detailed elsewhere.

Effects on General Clinical and Biologic Symptoms

The results are outlined in Table 2. There were no life-threatening side effects.

Clinical effects. Four patients (no. 1, 6, 9, and 10) with low-grade fever ranging from 37°C to 38°C, without evidence of overt infection showed a normalisation in body temperature within 2 days of treatment with anti-IL-6 MoAb. This was frequently associated with disappearance of fatigue and a slight but significant improvement of the performance status and pain.

Biologic effects. Except patient no. 2 (shortest treatment) and 3 (local treatment), all the patients developed further worsening of thrombocytopenia (35% to 86%; median, 40%). One patient with marked thrombocytopenia (no. 9, 17,000/µL) before therapy required platelet transfusion. Six of these 8 patients also showed neutrophil reduction (65% to 95%), including 1 due to toxic antibiotherapy (patient no. 7). Three patients (no. 2, 5, and 8) developed bacterial infections, which were lethal in patients no. 2 and 8. The
neutropenia was not different in these patients from that of the others.

Because C-reactive protein (CRP) production by freshly explanted human hepatocytes is dependent on IL-6 in vitro, CRP serum levels were determined before and during intravenous anti-IL-6 MoAb. Before treatment, CRP serum levels were elevated in all the patients, ranging from 5 to 160 mg/L (median, 60 mg/L; normal values, <1 mg/L by nephelometry). A significant reduction in CRP of at least 50% was observed in all the patients receiving anti-IL-6 therapy. Sustained suppression to undetectable levels (<1 mg) was observed in 3 patients (no. 4, 5, and 6) receiving more than 1 week of treatment (Fig 2). In the other 4 cases (no. 7, 8, 9, and 10), CRP serum levels were reduced by 60% to 96% but remained above normal levels (Fig 2 and Table 2). It is noteworthy that the maximum CRP serum level reduction correlates with the maximum and absolute platelet counts reduction (Table 2).

The daily production of IL-6 has been estimated as previously described by ourselves. Data are not evaluable in patients no. 1 and 2 (too short a treatment) and not available in patient no. 4. For the others, the daily IL-6 production ranged from 1.7 to more than 341 µg/d. Of note is that CRP was totally inhibited in patients with the lowest IL-6 production (no. 5 and 6, Table 2).

### Anti-proliferative Effects of Anti-IL-6 MoAb

**In vitro studies.** Mononuclear cells from bone marrow (no. 2, 3, 5, and 10), blood (no. 1, 3, 8, and 9), and pleural effusion (no. 3) samples were cultured as previously described in Patients, Materials, and Methods with anti-IL-6 MoAb or anti-IL-6 MoAb and IL-6; mab-8 was used in patient no. 1 and B-E8 in the other cases. In all patients exhibiting S phase values greater than 1%, complete inhibition of myeloma cell proliferation was observed (Table 3) as previously published by ourselves in many patients with MM. Similar results were previously published for patient no. 6. In agreement with these results, IL-6-dependent cell lines were established in 4 patients (no. 1, 3, 7, and 8).

**In vivo studies.** Concomitantly with in vitro investigations, in vivo cytokinetic studies were performed in patient no. 3 while receiving anti-IL-6 MoAb intrapleurally for a malignant pleural effusion and in patients no. 1, 4, 5 and 6.

Patient no. 3 with primary PCL exhibited primary treatment drug resistance with subsequent development of a malignant pleural effusion. Upon local administration of 20 mg of B-E8 anti-IL-6 MoAb on 3 successive days, a 80% decrease of the concentration of tumor cells and of their proliferative compartment (from 16% to 2.5% myeloma cells in S phase) was observed (Fig 3A). No diffusion of the anti-IL-6 MoAb was found outside the pleural fluid. In this case, the local concentration of MoAb was 20 µg/mL on day 1 of treatment, increasing up to 60 µg/mL on day 3. This finding was in agreement with a diffusion volume of 1 L. In these conditions, this in vivo model was very close to an in vitro situation. The dramatic decrease of myeloma cell proliferation and of myeloma cell counts during treatment was

### Table 3. Inhibition of Myeloma Cell Growth (Labeling Index) by the Anti-IL-6 MoAb In Vitro

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sample Origin</th>
<th>Controls</th>
<th>With Anti-IL-6 MoAb</th>
<th>With Anti-IL-6 MoAb and IL-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Blood</td>
<td>30</td>
<td>0.7</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>Bone marrow</td>
<td>21</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>3</td>
<td>Bone marrow</td>
<td>18</td>
<td>0.6</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>Peripheral blood</td>
<td>16</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>Pleural effusion</td>
<td>16</td>
<td>0.5</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Bone marrow</td>
<td>8</td>
<td>0.3</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>Bone marrow</td>
<td>1</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>8</td>
<td>Peripheral blood</td>
<td>1.5</td>
<td>0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

Values are the percentage of myeloma cells in S phase. See Patients, Materials, and Methods.
ANTI-IL-6 THERAPY IN MYELOMA

Fig 3. (A) Significant reduction in both myeloma cell counts and myeloma cells in S phase in patient no. 3 during B-E8 anti-IL-6 therapy. (B) Significant reduction in the percentages of myeloma cells in S phase in patient no. 1 during mab-8 anti-IL-6 therapy.

therefore in agreement with the inhibition of myeloma cell proliferation by the anti-IL-6 MoAb that was observed in short-term cultures in vitro in this patient (Table 3).

Patient no. 1 developed secondary PCL, with 11,200 myeloma cells/mL in peripheral blood and an S phase fraction of 30%. In our experience and that of others, such proliferative activity in peripheral blood was quite unusual. Considering this high proliferative activity and that B-E8 MoAb was administered intravenously, thus in the close contact of tumor cells, the situation was very similar to that of patient no. 3 and that of in vitro studies. Upon administration of gradually increasing doses of mab-8, in vivo drug levels increased progressively to 7.7 μg/mL on day 4 and myeloma cell proliferation decreased markedly in vivo, reaching a low S-phase fraction of 3% after 4 days (Fig 3B). The absolute increase in circulating myeloma cells to 55,000/μL throughout the 4 days of treatment with anti-IL-6 may have resulted from sustained tumor cell proliferation, albeit at a markedly reduced level of 3% versus 30% at the onset of therapy.

Patient no. 2 died quickly and was not evaluable for antiproliferative effects of anti-IL-6 MoAb. In patients no. 4, 5, and 6, a transient but significant reduction of myeloma labeling index was obtained within the bone marrow. In patient no. 4, a reduction from 19% to 3% of the myeloma bone marrow labeling index was observed, with a subsequent increase to 14%. In patients no. 5 and 6, a reduction from 1.5% and 4.5%, respectively, to 0% was noted. Disease progressed in the other 4 patients and no antiproliferative effect was documented.

Antitumoral Effects of Anti-IL-6 MoAb

None of the patients treated had improved outcome or achieved remission, as defined by standard clinical response criteria for MM. The observed effects after anti-IL-6 administration in this poor-risk patient population must therefore be categorized as biologic effects. Indeed, although tumor cell proliferation was inhibited in peripheral blood in 1 patient (no. 1) and in pleural effusion in another (no. 3), both died within 1 week due to their terminal disease stage. A third patient (no. 2) had central nervous system involvement and died on day 5. The remaining patients (no. 4 through 10) were treated for 13 to 68 days (median, 17 days). As emphasized in the previous section, a clear-cut objective antiproliferative effect was observed on malignant cells in vivo in 3 patients (no. 4, 5, and 6). Among them, 1 patient (no. 6) achieved 30% tumor cytoreduction for 2 months, but relapse occurred after stopping anti-IL-6 MoAb. Although patients no. 4 and 5 had significant (but transient) reduction in their marrow plasma cell labeling index, disease progressed. Furthermore, fast disease progression was observed in 4 other patients (no. 7, 8, 9, and 10). CRP synthesis was transiently inhibited in patient no. 9, in association with reduction of overall white blood cells and plasmablasts (86% inhibition) between days 3 and 6. However, a progression occurred on day 7 in conjunction with the emergence of human antibodies to Fc fragments of murine B-E8 MoAb that was no longer detectable. Of major interest (and as outlined in Table 2) a clear correlation was found between in vivo daily IL-6 production, inhibition of CRP synthesis, and antiproliferative effects. Such effects were only observed in patients no. 4, 5, and 6, presenting the lowest IL-6 production. In these 3 patients, the B-E8 MoAb was able to inhibit CRP. In the 4 other patients presenting the highest production of IL-6, the B-E8 MoAb was unable to completely inhibit CRP synthesis and thus IL-6. These results are summarized in Table 2.

DISCUSSION

In vitro studies performed in our patients receiving anti-IL-6 MoAb in vivo simply and clearly show that, among the various putative myeloma cell growth factors, IL-6 plays...
an essential role in controlling spontaneous myeloma cell proliferation in vitro.\(^2\) Indeed, adding anti-IL-6 MoAb dramatically inhibited the spontaneous proliferation of myeloma cells that occurred in 5-day cultures.\(^3\) These in vitro concentrations of anti-IL-6 MoAb was sufficient to neutralize 95% of the IL-6 produced in the short-term cultures. Moreover, IL-6-dependent myeloma cell lines have been obtained for some of these patients.\(^4\)

To discuss the effects of anti-IL-6 MoAb in vivo, one has first to assess the feasibility to block IL-6 activity in the close vicinity of tumor cells. The answer to this question has been made easy by our previous findings that anti-IL-6 MoAb induced large amounts of IL-6 to circulate in the form of stable immune complexes that have the same half-life as the free antibody (3 to 4 days).\(^5\) Thus, when stable plasma concentrations of anti-IL-6 MoAb and of IL-6/anti-IL-6 MoAb complexes are achieved (after 6 to 8 days of treatment), one can predict the ability of the anti-IL-6 MoAb to block IL-6 binding to the cell surface high-affinity IL-6 receptors according to the methodology we previously published.\(^6,7\) Interestingly, these predictions fitted perfectly well the inhibition of CRP production observed in these patients. CRP is an acute-phase protein whose production by human hepatocytes in primary cultures is controlled by IL-6.\(^7\) The present study shows that, in patients no. 5 and 6 producing low amounts of IL-6 (<4 µg/d), a complete inhibition of CRP production was found, unlike in patients with larger IL-6 production (>46 µg/d up to >300 µg/d). Actually, mathematical modelling predicts an inability to block IL-6 as soon as IL-6 production is greater than 18 µg/d (B. Klein, unpublished observations). The good value of CRP for predicting the effects of anti-IL-6 therapy based on the plasma concentrations of MoAb and IL-6/anti-IL-6 MoAb complexes is understandable. Indeed, IL-6 is mainly produced in the tumor environment in our patients treated with anti-IL-6 MoAb. It is carried to the liver in the form of monomeric complexes so that the ratio of the concentrations of these complexes to those of free MoAb should be similar to the ratio found in the plasma. In the tumor samples, the situation should be different. As IL-6 is produced in the tumor samples and as the anti-IL-6 MoAb has to diffuse to the tumor sample, the ratio of IL-6 anti-IL-6 MoAb complexes to free MoAb is compulsorily superior to that found in the plasma. In other words, it will be much more difficult to neutralize IL-6 in the tumor sample than to neutralize CRP production in the liver.

In this study, we got the opportunity to evaluate the anti-proliferative effects of anti-IL-6 MoAb knowing the concentrations of IL-6 and anti-IL-6 MoAb close to proliferating tumor cells. In patient no. 3, the anti-IL-6 MoAb was injected directly in the pleural effusion and did not diffuse outside the tumor site. In patient no. 1, all circulating tumor cells were proliferating (30% myeloma cells in the S phase). In these 2 cases, a dramatic inhibition of tumor proliferation was observed as it was observed for the same tumor cells in vitro. In the other patients, even as CRP production was not completely inhibited, it is easily understandable that no major antitumor activity was found. Thus, our study shows that, as soon as the anti-IL-6 MoAb is in sufficient amount to neutralize IL-6 activity in the close vicinity of the tumor cells, a dramatic inhibition of myeloma-cell proliferation is observed in vivo as it was observed in vitro. However, none of the patients treated had improved outcome or achieved remission as defined by standard clinical response criteria for MM. The observed effects after anti-IL-6 administration in this poor-risk patient population must therefore be categorized as biologic effects.

Among the other beneficial effects of anti-IL-6 MoAb observed, resolution of fever and hypercalcemia (data not shown) are of particular importance. The well-documented pyrogenic properties of IL-6\(^1\) were clearly shown in those patients with low-grade fever whose body temperature quickly normalized under anti-IL-6 therapy. Recent evidence shows that IL-6 also functions as a bone-resorbing factor especially in association with its receptor.\(^2\) A hypocalcemic effect was observed in a responsive patient, indicating that IL-6 might play a role in MM-induced bone resorption. Among the side effects observed, thrombocytopenia is of interest. Initial thrombocytopenia was observed in most of patients of this series. Subsequently to anti-IL-6 therapy, a further decline in platelet counts was observed in all cases. The involvement of IL-6 in primate thrombopoiesis is well documented,\(^24,25\) but the exact role of this cytokine in humans, in association with other cytokines, is not completely defined.

It is noteworthy that only 1 of 7 patients evaluated for human antibodies to murine anti-IL-6 MoAb showed strong immunization responsible for complete clearance of B-E8 anti-IL-6 MoAb and resulting in fast progression. Weak immunization was observed in patients no. 4, 5, and 6 who received the longest treatments.

In conclusion, our data show that administration of sufficient quantities of anti-IL-6 MoAb, resulting in inhibition of CRP production and neutralization of IL-6 production in vivo can block, at least transiently, the proliferation of the myeloma plasmablastic compartment. They confirm that IL-6 is an essential myeloma cell growth factor in vivo. However, many of our patients had severe disease and produced huge amounts of IL-6, making anti-IL-6 MoAb unable to neutralize them. Thus, clinical trials in patients in earlier disease stages are warranted. Considering the risk of immunization against the murine anti-IL-6 MoAb, humanized anti-IL-6 MoAb might prove useful, especially for treatment of patients with earlier stage disease.

**ACKNOWLEDGMENT**

We thank L. Bataille-Zagury for editing the English text and A. Bausain and P. Doiteau for typing the manuscript.

**REFERENCES**


Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

R Bataille, B Barlogie, ZY Lu, JF Rossi, T Lavabre-Bertrand, T Beck, J Wijdenes, J Brochier and B Klein